Maaz Aida, Blagbrough Ian S, De Bank Paul A
Department of Life Sciences, University of Bath, Bath BA2 7AY, UK.
Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK.
Pharmaceutics. 2024 May 16;16(5):669. doi: 10.3390/pharmaceutics16050669.
A general procedure to prepare gold nanourchins (GNUs) via a seed-mediated method was followed using dopamine hydrochloride as a reducing agent and silver nitrate salt (AgNO) as a shape-directing agent. The novelty of this study comes from the successful incorporation of the prepared gold urchins as an aqueous suspension in a nasal pressurized metered dose inhaler (pMDI) formulation and the investigation of their potential for olfactory targeting for direct nose-to-brain drug delivery (NTBDD). The developed pMDI formulation was composed of 0.025% / GNUs, 2% / Milli-Q water, and 2% / EtOH, with the balance of the formulation being HFA134a propellant. Particle integrity and aerosolization performance were examined using an aerosol exposure system, whereas the nasal deposition profile was tested in a sectioned anatomical replica of human nasal airways. The compatibility of the gold dispersion with the nasal epithelial cell line RPMI 2650 was also investigated in this study. Colloidal gold was found to be stable following six-month storage at 4 °C and during the lyophilization process utilizing a pectin matrix for complete re-dispersibility in water. The GNUs were intact and discrete following atomization via a pMDI, and 13% of the delivered particles were detected beyond the nasal valve, the narrowest region in the nasal cavity, out of which 5.6% was recovered from the olfactory region. Moreover, the formulation was found to be compatible with the human nasal epithelium cell line RPMI 2650 and excellent cell viability was observed. The formulated GNU-HFA-based pMDI is a promising approach for intranasal drug delivery, including deposition in the olfactory region, which could be employed for NTBDD applications.
采用种子介导法制备金纳米海胆(GNU)的一般程序,使用盐酸多巴胺作为还原剂,硝酸银盐(AgNO)作为形状导向剂。本研究的新颖之处在于成功地将制备好的金纳米海胆水悬浮液纳入鼻腔加压定量吸入器(pMDI)制剂中,并研究了其用于嗅觉靶向直接鼻脑给药(NTBDD)的潜力。所开发的pMDI制剂由0.025% / GNU、2% / 超纯水和2% / 乙醇组成,制剂的其余部分为HFA134a推进剂。使用气溶胶暴露系统检查颗粒完整性和气雾化性能,而在人体鼻气道的分段解剖模型中测试鼻腔沉积分布。本研究还考察了金分散体与鼻上皮细胞系RPMI 2650的相容性。发现胶体金在4℃下储存六个月以及在冻干过程中(利用果胶基质以实现完全再分散于水中)后是稳定的。通过pMDI雾化后,GNU完整且离散,在鼻腔最狭窄区域鼻瓣之外检测到13%的递送颗粒,其中5.6%从嗅觉区域回收。此外,发现该制剂与人类鼻上皮细胞系RPMI 2650相容,并观察到优异的细胞活力。基于GNU - HFA的配方pMDI是一种有前景的鼻内给药方法,包括在嗅觉区域的沉积,可用于NTBDD应用。